返回列表

招银证券:给予信达生物(01801.HK)“增持”评级 目标价55.21港元

  招银证券11月5日发布公告。Maintain BUY. Innovent aims to develop its global business, while protecting the interests of its broad shareholder base. We remain confident towards Innovent’s strong product sales, improving cost efficiency, and potential of overseas development. We maintain our DCF-based TP unchanged at HK$55.21 (WACC: 10.0%, terminal growth rate: 3.5%).

  • 用户注册

    扫码注册或下载尊嘉金融App注册
  • 极速开户

    2分钟填写开户信息,即时开户成功
  • 0佣交易

    随时随地开启港美A股0佣金交易

1个账户、1笔资金
0佣金买卖港股、美股、A股